Operating Room, West China Hospital, Sichuan University, West China School of Nursing, Chengdu, China.
Genet Res (Camb). 2023 Apr 6;2023:3898610. doi: 10.1155/2023/3898610. eCollection 2023.
On a global scale, renal cell carcinoma (RCC) is the second most common form of cancer and the 10th leading cause of cancer-related deaths. There are about 70% of cases of RCC that are clear cell renal cell carcinomas (ccRCCs). This study explores possible targets for immune therapy in patients with RCC. In the recent years, immunotherapy has been applied to RCC patients. In order to identify genes that are closely associated with immune cells, a weighted gene coexpression network analysis (WGCNA) was conducted. A close association was found between genes involved in MEred and M0 macrophages, M1 macrophages, and M2 macrophages. A prognostic prediction model is subsequently developed by incorporating the OS and the expression level of key genes from the RCC cohort into a univariate COX regression analysis, a multivariate COX regression analysis, and a combined COX regression analysis. We finally discovered that 6 genes are closely associated with the prognosis of RCC patients, including SLC16A12, SLC2A9, IGF2BP2, EMX2, ANK3, and METTL7A. The survival analysis proved the prognostic prediction value of the model. The 1-year, 3-year, and 5-year AUC of ROC curves are 0.759, 0.723, and 0.733, respectively. For clinical ROC curves, the AUC score for risk score, stage, grade, and stage is 0.759, 0.824, 0722, and 0.736, respectively. The nomogram was constructed for better prognosis prediction of RCC patients. In addition, GSVA and GO enrichment analysis was performed to explore the potential pathways that are closely associated with genes involved in the prognostic prediction model. Accordingly, our study demonstrates that immune cells play a crucial role in RCC infiltration. The development of a prognostic prediction model is a potential new prognostic biomarker and potential immunotherapy target for tumors.
在全球范围内，肾细胞癌（RCC）是第二常见的癌症类型，也是癌症相关死亡的第十大主要原因。大约 70%的 RCC 病例为透明细胞肾细胞癌（ccRCC）。本研究探讨了 RCC 患者免疫治疗的可能靶点。近年来，免疫疗法已应用于 RCC 患者。为了鉴定与免疫细胞密切相关的基因，进行了加权基因共表达网络分析（WGCNA）。发现与 MEred 和 M0 巨噬细胞、M1 巨噬细胞和 M2 巨噬细胞相关的基因密切相关。随后通过单变量 COX 回归分析、多变量 COX 回归分析和联合 COX 回归分析，将 RCC 队列中的 OS 和关键基因的表达水平纳入其中，建立了预后预测模型。最后发现 6 个基因与 RCC 患者的预后密切相关，包括 SLC16A12、SLC2A9、IGF2BP2、EMX2、ANK3 和 METTL7A。生存分析证明了该模型的预后预测价值。ROC 曲线的 1 年、3 年和 5 年 AUC 分别为 0.759、0.723 和 0.733。对于临床 ROC 曲线，风险评分、分期、分级和阶段的 AUC 评分为 0.759、0.824、0.722 和 0.736。为了更好地预测 RCC 患者的预后，构建了列线图。此外，还进行了 GSVA 和 GO 富集分析，以探讨与预后预测模型相关基因密切相关的潜在途径。因此，本研究表明免疫细胞在 RCC 浸润中起关键作用。预后预测模型的开发为肿瘤提供了一种新的潜在预后生物标志物和潜在免疫治疗靶点。
